Stenahm Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Stenahm Asset Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-19,400	Closed	-$2.5M	–	29
2021 Q1	$2.5M	Sell	19,400 -9,600	-33%	-$1.46M	1.76%	19
2020 Q4	$4.84M	Buy	+29,000	New	+$4.8M	4.07%	13

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Stenahm Asset Management's ASND Position: Q2 2021 in Review

Stenahm Asset Management sold out of Ascendis Pharma A/S (ASND) in Q2 2021, closing a stake of 19,400 shares — an estimated $2.5M sold.

Stenahm Asset Management first reported a position in ASND in Q4 2020 and held it in 2 quarters. The position peaked at $4.84M in Q4 2020. 171 funds tracked by Wall St. Rank hold ASND as of Q2 2021.

Stenahm Asset Management reported no remaining Ascendis Pharma A/S position as of Q2 2021 after selling out during the quarter.
Stenahm Asset Management sold 19,400 Ascendis Pharma A/S shares in Q2 2021, an estimated $2.5M.
Stenahm Asset Management first reported a position in Ascendis Pharma A/S in Q4 2020 and held it in 2 quarters.
Stenahm Asset Management's Ascendis Pharma A/S position peaked at $4.84M in Q4 2020.
171 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2021.

Based on Stenahm Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.